Table 3.

Concentrations of FoxP3⁺CD4⁺CD25⁺ cells during treatment with ipilimumab and ECT

FoxP3+CD4+CD25+	FoxP3+CD4+CD25+	CD4+tot	CD4+tot
Week 0 (%)	Week 12 (%)	Week 0 (%)	Week 12 (%)
2	3	36.2	26
4	5	54	45
2.1	4.7	27.9	30
3	2.3	34	24
2.1	3.3	35.2	34
2	0.7	50.2	50
0.4	0.6	34	30
3.4	3.7	56	50.2
5	4.5	33.7	30.8
0.4	0.4	53.6	51
6	7.4	25.9	25
5	5.1	31	30
4	4.1	32.8	34.1
0.7	0.6	54	50.3
0.6	0.4	33	30.5